- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03482531
Assessing a Predicted Time to Delivery in the Context of Cervical Ripening With Dinoprostone Vaginal Insert
Assessing, Depending on Personalized Manner, a Predicted Time to Delivery in the Context of Cervical Ripening With Dinoprostone Vaginal Insert
Induction of labor is a common obstetric procedure that is routinely performed worldwide. However, when cervical conditions are not favorable (bishop <6), induction of labor is preceded by cervical ripening, usually with prostaglandins. The method of ripening most commonly used in France (89% of maternity wards) is the dinoprostone vaginal insert. In the majority of hospitals in France, dinoprostone vaginal inserts are usually placed in the morning, because of the higher availability of personnel (midwives and nurses). However, morning placement might increase the likelihood of the delivery occurring at night, since the mean interval between the insert placement and delivery is about 13 to 20 hours. Many studies have now shown that the risk of obstetrical complications, as well as neonatal morbidity and mortality is increased when deliveries occur at night. Several factors have been suggested behind the increased morbidity at night, including the lower number of personnel working, the fatigue associated with night work and the disruption of the circadian rhythm, and the insufficient supervision of residents.
Very few studies have evaluated the importance of the timing of placement of the intravaginal dinoprostone insert, and its influence on the occurrence of night deliveries. Some investigators have recently performed a retrospective study at Angers university hospital that assessed the time interval between placing the dinoprostone vaginal insert and delivery, as well as the factors impacting the time to delivery, and found that nulliparity, obesity, a closed cervix on initial examination, and intact membranes at the time of insertion increased the time to delivery. Moreover, the investigators proposed a regression equation that allows to calculate the mean time from insert placement to delivery for each patient, and have decided to incorporate it in the routine practice.
The investigators have decided to analyze the validity of the mathematical model. The consequence would be, thanks to a personalized timing for placement of dinoprostone vaginal insert based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes), a decreased number of deliveries occurring between 12 p.m. and 6 a.m.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a before-after, retrospective and prospective monocentric study. Patients in the "before" group were part of another study which are currently in the process of publishing and were retrospectively included, whereas patients in the "after" group will be prospectively included.
In the "before" group, the investigators retrospectively included 405 patients who had a dinoprostone vaginal insert for cervical ripening before induction of labor, between January 2015 and September 2016. The main outcome of the previous study was to evaluate the time interval between placing the dinoprostone vaginal insert and delivery. One of the secondary objectives was to determine the factors that would impact the time to delivery. Multivariate and regression analysis showed that the factors significantly increasing the time to delivery were: Nulliparity, obesity, a closed cervix on initial examination, and intact membranes at the time of insertion. The investigators also described a regression equation that allows to calculate the mean time from insert placement to delivery for each patient:
Y = 961,188 - 80,346 x parity + 21,437 x Body Mass Index (BMI) - 165,263 x cervical dilation- 241,759 x Premature rupture of membranes.
Following this study, the investigators decided to modify the routine procedures on the maternity ward and incorporate the equation when scheduling patients for cervical ripening with vaginal dinoprostone insert. The aim is to have a more personalized insertion schedule that would lower the number of deliveries occurring between midnight and 6 a.m., since it has been proven that there is a higher risk of obstetrical morbidity with night-time labor and delivery.
The investigators will prospectively include all eligible patients with a vaginal dinoprostone insert for cervical ripening during the next two years, starting on April 1st, 2018. At Angers hospital, there are around 600 cases of dinoprostone vaginal inserts per year, so 400 to 500 patients will be included during the study's duration. The investigators will then compare the outcomes in these patients that will comprise the "after" group, to the outcomes of patients in the "before" group, who delivered before the implementation of the new scheduling process. The investigators will thus be able to able to assess whether the mathematical model they suggested to estimate time to delivery and the personalized insertion timings have been confirmed. Then, subsequently, the objective is to analyze whether the use of the personalized scheduling based on the mathematical model they described would decrease the rate of nocturnal deliveries (between midnight and 6 a.m.).
The research project has been approved by the ethics committee of Angers university hospital on January 31st, 2018.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Maine Et Loire
-
Angers, Maine Et Loire, France, 49000
- Recruiting
- Angers University Hospital
-
Contact:
- BOUET Pierre-emmanuel, doctor
- Phone Number: (+33) 02.41.35.42.13
- Email: PierreEmmanuel.Bouet@chu-angers.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- have cervical ripening with the dinoprostone vaginal insert
- 34 weeks gestational age (GA) and beyond
- singleton pregnancies
- cephalic presentations
Exclusion Criteria:
- term < 34 weeks GA
- previous history of cesarean section
- women who refuse to participate in the study or have their data used.
- twin pregnancy
- prostaglandin allergies
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
before group
In the "before" group, the investigators retrospectively included 405 patients who had a dinoprostone vaginal insert for cervical ripening before induction of labor, between January 2015 and September 2016. Multivariate and regression analysis showed that the factors significantly increasing the time to delivery were: Nulliparity, obesity, a closed cervix on initial examination, and intact membranes at the time of insertion. The investigators also described a regression equation that allows to calculate the mean time from insert placement to delivery for each patient. |
|
after group
The investigators will prospectively include all eligible patients with a vaginal dinoprostone insert for cervical ripening during the next two years, starting on April 1st, 2018. At Angers hospital, there are around 600 cases of dinoprostone vaginal inserts per year, so the investigators will be able to include 400 to 500 patients during the study's duration. The equation will be incorporated when scheduling patients for cervical ripening with vaginal dinoprostone insert. The main objective of this study is to analyze to evaluate our mathematical model. One of the secondary objectives is to analyze whether the use of the personalized scheduling based on the mathematical model would decrease the rate of nocturnal deliveries (between midnight and 6 a.m.). |
mathematical model: regression equation that calculates the mean time from insert placement to delivery for each patient, based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference (in minutes) between the actual time to delivery compared to the predicted time
Time Frame: 2 days
|
there will be different categories:
|
2 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rate of deliveries
Time Frame: 2 years
|
rate of deliveries occurring between midnight and 6 a.m.
following cervical ripening with dinoprostone vaginal insert.
|
2 years
|
the Apgar score
Time Frame: 1, 3 and 5 minutes after delivery
|
Apgar score lower than 7 at 1, 3 and 5 minutes.
Apgar score lower than 7 at 5 minutes is correlated on the immediate child's development
|
1, 3 and 5 minutes after delivery
|
neonatal potential of hydrogen (pH)
Time Frame: 1 hour
|
|
1 hour
|
neonatal intensive care hospitalization
Time Frame: 12 hours
|
The rate of neonatal intensive care hospitalization in the immediate postpartum and during the 12 hours after delivery
|
12 hours
|
post-partum bleeding
Time Frame: 24 hours
|
|
24 hours
|
Operative deliveries
Time Frame: 2 years
|
the rate of forceps deliveries and vacuum extractions during the study duration
|
2 years
|
Cesarean sections
Time Frame: 2 years
|
the rate of cesarean sections during the study duration
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PHRC 2018-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dinoprostone Vaginal Insert
-
Zeynep Kamil Maternity and Pediatric Research and...CompletedVaginal Infection | Labor Induction | Effect Increased | Dinoprostone Vaginal InsertTurkey
-
Navy Medical Center San DiegoNot yet recruitingSteroid Ophthalmic Insert
-
Cairo UniversityCompletedDinoprostone TimingEgypt
-
Navamindradhiraj UniversityUnknownConstrained Insert in Knee ArthroplastyThailand
-
The Catholic University of KoreaUnknownOsteoarthritis, Ultra-Congruent(UC) Insert
-
University of LouisvilleCompletedPhysical Activity | Surgery | Vaginal Hysterectomy | Vaginal SurgeryUnited States
-
El-Galaa Military Medical ComplexCompletedVaginal Infection | Vaginal Cuff Dehiscence | Vaginal HematomaEgypt
-
Assiut UniversityUnknown
-
Universita degli Studi di CataniaProBioEtnaCompleted
Clinical Trials on mathematical model
-
Nantes University HospitalCompleted
-
Dana-Farber Cancer InstituteCompleted
-
University of VirginiaNot yet recruitingMyocardial InfarctionUnited States
-
Melike Yilmaz AkdagKanuni Sultan Suleyman Training and Research HospitalCompleted
-
New Mexico Cancer Care AllianceCompletedBreast CancerUnited States
-
Johnson & Johnson Surgical Vision, Inc.TerminatedCataractUnited States
-
National University, SingaporeUnknown
-
Medtronic CardiovascularCompleted
-
Sun Yat-sen UniversityQueen's University, Belfast; Orbis; Aravind Eye Care System; Padmashree Dr. D.... and other collaboratorsCompleted
-
Lund UniversityAnti-Diabetic Food CentreCompleted